Literature DB >> 9040728

Longitudinal change in basal ganglia volume in patients with Huntington's disease.

E H Aylward1, Q Li, O C Stine, N Ranen, M Sherr, P E Barta, F W Bylsma, G D Pearlson, C A Ross.   

Abstract

Cross-sectional MRI studies demonstrating an association between caudate atrophy and symptom severity and duration of symptoms in patients with Huntington's disease (HD) have been assumed to reflect longitudinal changes in basal ganglia, but such neuropathologic progression has never been directly demonstrated. Subjects in the current study were 23 HD patients at various stages of the disorder who had two MRI images at least 10 months apart (mean interimage interval = 20.8 months). We measured volumes of caudate, putamen, and globus pallidus blind to the order of the images. For each structure, we calculated a change score by subtracting the volume obtained on the follow-up imaging from that obtained on the initial imaging. Results indicated significant decreases over time in caudate, putamen, and total basal ganglia volume. Age at onset and length of trinucleotide repeat correlated significantly with amount of volume change in caudate and total basal ganglia, even after controlling for length of interimage interval, duration of disease, and measures of symptom severity. Amount of change in basal ganglia structures was not significantly correlated with neurologic symptom severity at the time of the initial imaging or duration of symptoms. This is the first longitudinal MRI study to document progressive basal ganglia atrophy in HD, and suggests that quantitative neuroimaging with serial MRI may be useful in monitoring effectiveness of potential treatments. In addition, demonstration of greater rate of basal ganglia atrophy in patients with earlier symptom onset suggests that treatment effects may be more quickly observed in this subgroup of patients than in the general HD population.

Entities:  

Mesh:

Year:  1997        PMID: 9040728     DOI: 10.1212/wnl.48.2.394

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  64 in total

1.  Comorbidities of obsessive and compulsive symptoms in Huntington's disease.

Authors:  Karen E Anderson; Carissa R Gehl; Karen S Marder; Leigh J Beglinger; Jane S Paulsen
Journal:  J Nerv Ment Dis       Date:  2010-05       Impact factor: 2.254

2.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

Review 3.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

4.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

5.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

6.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

Review 7.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

8.  Visual scanning and cognitive performance in prediagnostic and early-stage Huntington's disease.

Authors:  Tanya Blekher; Marjorie R Weaver; Jeanine Marshall; Siu Hui; Jacqueline Gray Jackson; Julie C Stout; Xabier Beristain; Joanne Wojcieszek; Robert D Yee; Tatiana M Foroud
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

Review 9.  "Pre-symptomatic" Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Handb Clin Neurol       Date:  2008

Review 10.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.